[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.134.98. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Comment & Response
August 2018

Questioning the Associations of ω-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks

Author Affiliations
  • 1Department of Medical and Surgical Sciences, Sant’Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
JAMA Cardiol. 2018;3(8):780-781. doi:10.1001/jamacardio.2018.1306

To the Editor Several recent meta-analyses of randomized clinical trials report contrasting results in regards to the protective effect of dietary supplementation with ω-3 polyunsaturated fatty acids (PUFAs) on cardiovascular disease risk. Based on these data, the American Heart Association recently modulated their suggestion on ω-3 PUFA supplementation, concluding it has potential usefulness in secondary prevention patients.1 In their meta-analysis carried out on 77 917 high-risk individuals participating in 10 trials, Aung et al2 further contrast the American Heart Association statement by demonstrating that ω-3 PUFAs supplementation was not associated with reduction in the risk of any vascular outcome.

×